Opendata, web and dolomites

ADHERE TERMINATED

Aptamer nanostructures dual-targeted to the HER receptor family for cancer therapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ADHERE project word cloud

Explore the words cloud of the ADHERE project. It provides you a very rough idea of what is the project "ADHERE" about.

bioengineering    encompasses    wp3    receptor    advantageous    resistance    single    university    position    zernike    dual    polymer    valuable    cellular    clinical    receptors    wp1    her1    antigens    gain    directed    time    reducing    young    me    disadvantages    institutes    outcome    dna    nanomaterials    bind    additional    background    multiple    aptamer    stranded    types    members    skills    therapeutics    material    her2    science    immunotherapy    cancer    training    binding    strategy    vitro    immunoglobulins    integrate    multivalent    physicochemical    materials    therapy    drug    wp2    world    transferable    strengthen    host    cell    receive    nanostructures    ligands    molecule    fashion    egfr    perspectives    bispecific    cells    msca    form    expressing    extensive    career    deals    adhere    aptamers    oligonucleotides    fellowship    vivo    chemistry    groningen    executed    netherlands    alternative    myself    anti    positioned    24    superior    scientist   

Project "ADHERE" data sheet

The following table provides information about the project.

Coordinator
RIJKSUNIVERSITEIT GRONINGEN 

Organization address
address: Broerstraat 5
city: GRONINGEN
postcode: 9712CP
website: www.rug.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Project website http://www.rug.nl/research/zernike/polymer-chemistry-and-bioengineering/crielaard-group/
 Total cost 177˙598 €
 EC max contribution 177˙598 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2015
 Funding Scheme MSCA-IF-EF-RI
 Starting year 2016
 Duration (year-month-day) from 2016-03-01   to  2018-02-28

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    RIJKSUNIVERSITEIT GRONINGEN NL (GRONINGEN) coordinator 177˙598.00

Map

 Project objective

The proposed research programme deals with the development of aptamer nanostructures for targeted cancer therapy. Immunotherapy encompasses a growing field of anti-cancer therapeutics that target cancer cells expressing specific antigens, such as members of the HER receptor. Currently, immunoglobulins directed to HER1, better known as EGFR, and HER2 are used in the clinical management of several types of cancer. There are, however, several disadvantages associated with the production and application of immunoglobulins. Moreover, there is evidence that dual-targeting of multiple receptors at the same time is advantageous for improving clinical outcome and reducing drug resistance. Aptamers, which are short single-stranded oligonucleotides that can bind a target molecule in a similar fashion as immunoglobulins, may form, due to their physicochemical properties, a superior alternative strategy for targeted cancer therapy. In ADHERE, I will design (WP1) and investigate in vitro (WP2) and in vivo (WP3) the use of aptamer nanostructures with bispecific (against both EGFR and HER2) and multivalent (up to 4 binding ligands) targeting properties for cancer cell targeting. The 24-month research project will be executed at the department of Polymer Chemistry and Bioengineering at the Zernike Institute for Advanced Materials, University of Groningen, The Netherlands. The aim of this MSCA IF fellowship is to integrate my extensive background in targeted drug delivery and cellular therapeutics within the host institute, which is highly experienced with DNA nanomaterials and is positioned among the top 10 institutes of the world in the field of material science. Importantly, this fellowship will strengthen my career perspectives, by allowing me to gain valuable new transferable skills and receive additional high-level training. This will enable me to position myself as a leading young scientist in the field of clinical nanomaterials.

 Publications

year authors and title journal last update
List of publications.
2017 Bart J. Crielaard, Twan Lammers, Stefano Rivella
Targeting iron metabolism in drug discovery and delivery
published pages: 400-423, ISSN: 1474-1776, DOI: 10.1038/nrd.2016.248
Nature Reviews Drug Discovery 16/6 2019-06-13

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ADHERE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ADHERE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

RAMBEA (2019)

Realistic Assessment of Historical Masonry Bridges under Extreme Environmental Actions

Read More  

PROSPER (2019)

Politics of Rulemaking, Orchestration of Standards, and Private Economic Regulations

Read More  

IRF4 Degradation (2019)

Using a novel protein degradation approach to uncover IRF4-regulated genes in plasma cells

Read More